COVID-19 Coronavirus Real Time PCR Kit

COVID-19 Coronavirus Real Time PCR Kit was developed and manufactured by bioPerfectus Technologies

Size: 50 Tests
Run Time: 72 Minutes
Sample Type: Nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs, midturbinate nasal swabs, nasal aspirates, nasal washes, bronchoalveolar lavage (BAL) fluid and sputum
Species Sample: Human
Sample Size: 5 µL
Alternative Names: Serology, Coronavirus, COVID-19, Corona, Serological
IVD, CE-Marked

Assay Principle

The oligonucleotide primers and probes for specific detection of SARS-CoV-2 are selected from regions of Open Reading Frame 1ab (ORF1ab) and the nucleocapsid gene (N) of the SARS-CoV-2 genome. The kit includes primers/probes that are specific for the ORF1ab gene (probe labeled with FAM) and N gene (probe labeled with VIC) of SARS-CoV-2. In addition, the kit also contains primers and a probe (labeled with CY5) for the human RNase P gene as an endogenous internal control for specimen integrity, nucleic acid isolation, amplification and detection.
RNA isolated and purified from upper and lower respiratory tract specimens is reverse transcribed to cDNA and amplified in a Real-time PCR instrument using one-step Master Mix. Probes consist of a reporter dye at the 5’ end and quenching dye at the 3’ end. The fluorescent signals emitted from the reporter dye are absorbed by the quencher. During PCR amplification, probes hybridized to amplified templates are degraded by the Taq DNA polymerase with 5’-3’ exonuclease activity, thereby separating the reporter dye and quencher and generating fluorescent signals that increase with each cycle. The PCR instrument automatically draws a real-time amplification curve for each optical channel based on the signal change, and calculates cycle threshold (Ct) values (the point at which fluorescence is detectable above background) that are interpreted by the operator to determine the presence/absence of SARS-CoV-2 RNA.

Information for US Customers

During this crisis, steps are being taken to ensure that we can provide access to quality products for diagnostic testing. The Food and Drug Administration (FDA) has issued guidance which allows for distribution of the serological tests. At this time, the kits are released for sale in the United States under the provisions outlined in Section D of Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency.

FDA EUA Number: EUA201047

Per the aforementioned guidance, the following statements are required:

• This test has not been reviewed by the FDA.
• Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus.
• Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
• Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
• Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

This kit is only provided for use by clinical laboratories or to healthcare workers for point-of-care testing, and not for at home testing.

Products Related to Coronavirus COVID-19 IgM ELISA Assay

Coronavirus COVID-19 IgG ELISA Assay Kit
Coronavirus COVID-19 IgM ELISA Assay Kit
Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay
Anti-SARS-CoV-2 (S1, S2, N) IgG ELISA Assay Kit

EagleBio在人类中，冠状病毒会引起呼吸道感染。冠状病毒由几种蛋白质组成，包括刺突（S），包膜（E），膜（M）和核衣壳（N）。结果表明，刺突蛋白与血管紧张素转化酶2（ACE2）受体保持足够的亲和力，可将其用作细胞进入的机制。人们主要认为冠状病毒在人与人之间的传播是通过打喷嚏和咳嗽产生的呼吸道飞沫在亲密接触者之间发生的。IgG是响应抗原产生的最丰富的免疫球蛋白，在长期暴露后会保持在体内。Eagle Biosciences仅提供最优质的测定以满足您的需求，并在这些艰难的时期内为您提供最佳的客户服务。